The Effective Statistician - in association with PSI Podcast Por Alexander Schacht and Benjamin Piske biometricians statisticians and leaders in the pharma industry capa

The Effective Statistician - in association with PSI

The Effective Statistician - in association with PSI

De: Alexander Schacht and Benjamin Piske biometricians statisticians and leaders in the pharma industry
Ouça grátis

Sobre este áudio

 The podcast from statisticians for statisticians to have a bigger impact at work. This podcast is set up in association with PSI - Promoting Statistical Insight. This podcast helps you to grow your leadership skills, learn about ongoing discussions in the scientific community, build you knowledge about the health sector and be more efficient at work. This podcast helps statisticians at all levels with and without management experience. It is targeted towards the health, but lots of topics will be important for the wider data scientists community.Alexander Schacht Ciências
Episódios
  • Top 6: What is EU HTA and why should statisticians care?

    Top 6: What is EU HTA and why should statisticians care?
    Sep 1 2025
    This is one of our most downloaded episodes ever, and I’m excited to bring it back in this replay. In this conversation, I spoke with Lara Wolfson (MSD) and Anders Gorst-Rasmussen (Novo Nordisk) about EU HTA (European Union Health Technology Assessment): what it is, why it’s coming, and why statisticians like us must pay attention. If you’ve ever wondered whether your approach to safety analysis is leading to misleading conclusions, this episode is a must-listen.
    Exibir mais Exibir menos
    36 minutos
  • Top 5: The analysis of adverse events done right

    Top 5: The analysis of adverse events done right
    Aug 25 2025
    We’re bringing back one of our most downloaded episodes ever – a deep dive into how adverse events should be analyzed properly. This conversation with Jan Beyersmann and Kaspar Rufibach is packed with methodological insights and practical implications for statisticians working in clinical trials. Adverse event (AE) analysis has long been approached differently from efficacy analysis, often using overly simplistic methods that can bias results. In this episode, we discuss why that’s a problem – and how the SAVVY collaboration (Survival analysis for AdVerse events with Varying follow-up times) is pushing the field forward. Together with academia and multiple pharma companies, this collaboration tackled the issue of AE analysis using real randomized trial data, not just simulations. The findings show how common methods can underestimate or overestimate event probabilities and how established statistical methods can be applied more consistently to ensure fair benefit–risk assessments. If you’ve ever wondered whether your approach to safety analysis is leading to misleading conclusions, this episode is a must-listen.
    Exibir mais Exibir menos
    53 minutos
  • Replay: R vs SAS - which is the better tool in pharmaceutical research

    Replay: R vs SAS - which is the better tool in pharmaceutical research
    Aug 11 2025
    In this special replay of one of our all-time most popular episodes, we dive deep into one of the most debated topics in the pharmaceutical industry: R vs SAS. Together with Thomas Neitmann and my co-host Sam Gardner, we compare these two powerful statistical programming tools from multiple angles — ease of learning, day-to-day usability, community support, visualization capabilities, regulatory acceptance, and more. Whether you are a seasoned SAS programmer, an R enthusiast, or someone deciding which tool to focus on, this conversation will give you valuable insights into where each shines, where they struggle, and how the industry is evolving.
    Exibir mais Exibir menos
    42 minutos
Ainda não há avaliações